用户,您好,欢迎您进入NSTL重点领域信息门户! 登录 | 注册  帮助中心
重点领域信息门户
您当前的位置: 首页 > [2018年第3期]情报条目详细信息

编译内容

编译服务: 心血管疾病防治 编译者: 张燕舞 编译时间: May 22, 2018 浏 览 量: 1

冠状动脉旁路移植手术(CABG)后给予长期阿司匹林预防大隐静脉移植物闭塞并减少心血管不良事件的发生率。 有人认为加入有效的P2Y12受体阻断剂如替格瑞洛可能会进一步改善预后。 在DACAB试验中,接受CABG的500名患者在术后24小时内被随机分配为替格瑞洛加阿司匹林,单用替格瑞洛或单用阿司匹林。 通过心血管成像确定的主要终点,一年的隐静脉移植通畅分别发生在三组静脉移植物中约89%,83%和77%。 虽然替卡格雷与阿司匹林的添加统计学上比单独使用阿司匹林更有效,但我们不推荐使用它,并担心增加出血风险的可能性,并等待临床结果的临床试验结果。

Importance The effect of ticagrelor with or without aspirin on saphenous vein graft patency in patients undergoing coronary artery bypass grafting (CABG) is unknown.

Objective To compare the effect of ticagrelor + aspirin or ticagrelor alone vs aspirin alone on saphenous vein graft patency 1 year after CABG.

Design, Setting, and Participants Randomized, multicenter, open-label, clinical trial among 6 tertiary hospitals in China. Eligible patients were aged 18 to 80 years with indications for elective CABG. Patients requiring urgent revascularization, concomitant cardiac surgery, dual antiplatelet or vitamin K antagonist therapy post-CABG, and who were at risk of serious bleeding were excluded. From July 2014 until November 2015, 1256 patients were identified and 500 were enrolled. Follow-up was completed in January 2017.

Interventions Patients were randomized (1:1:1) to start ticagrelor (90 mg twice daily) + aspirin (100 mg once daily) (n = 168), ticagrelor (90 mg twice daily) (n = 166), or aspirin (100 mg once daily) (n = 166) within 24 hours post-CABG. Neither patients nor treating physicians were blinded to allocation.

Main Outcomes and Measures Primary outcome was saphenous vein graft patency 1 year after CABG (FitzGibbon grade A) adjudicated independently by a committee blinded to allocation. Saphenous vein graft patency was assessed by multislice computed tomographic angiography or coronary angiography.

Results Among 500 randomized patients (mean age, 63.6 years; women, 91 [18.2%]), 461 (92.2%) completed the trial. Saphenous vein graft patency rates 1 year post-CABG were 88.7% (432 of 487 vein grafts) with ticagrelor + aspirin; 82.8% (404 of 488 vein grafts) with ticagrelor alone; and 76.5% (371 of 485 vein grafts) with aspirin alone. The difference between ticagrelor + aspirin vs aspirin alone was statistically significant (12.2% [95% CI, 5.2% to 19.2%]; P < .001), whereas the difference between ticagrelor alone vs aspirin alone was not statistically significant (6.3% [95% CI, -1.1% to 13.7%]; P = .10). Five major bleeding episodes occurred during 1 year of follow-up (3 with ticagrelor + aspirin; 2 with ticagrelor alone).

Conclusions and Relevance Among patients undergoing elective CABG with saphenous vein grafting, ticagrelor + aspirin significantly increased graft patency after 1 year vs aspirin alone; there was no significant difference between ticagrelor alone and aspirin alone. Further research with more patients is needed to assess comparative bleeding risks.Trial Registration clinicaltrials.gov Identifier: NCT02201771.

  
提供服务
导出本资源